Back Clear search

The Drug-Induced Cardiotoxicity Website and App

Bevacizumab

No undisputable evidence for bevacizumab-induced ILD as of Oct, 2014

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Myocardial dysfunction - Heart failure

I.a

Left or biventricular dysfunction/failure

VI - Cardiomyopathy

VI.a

Cardiomyopathy (acute, subacute, chronic)
VI.c

Takotsubo (stress) cardiomyopathy

VII - Cardiotoxicity

VII.a

Cardiotoxicity

XI - Pulmonary vasculopathies

XI.a

Pulmonary arterial hypertension

XIII - Thrombosis - Embolism

XIII.a

Pulmonary embolism - Venous thrombosis/thromboembolism
XIII.o

Systemic arterial thrombosis

XIV - Pleural involvement

XIV.k

Esophageal pleural fistula

XVI - Hemorrhage - Bleeding - Hematoma

XVI.e

Alveolar hemorrhage (AH), diffuse AH (DAH)
XVI.i

Hemoptysis
XVI.j

Major/massive hemoptysis
XVI.o

Epistaxis

XVIII - Aortic involvement

XVIII.d

Aortitis

XX - Vasculitis

XX.d

Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

XXII - Acute respiratory/cardiorespiratory failure

XXII.b

ARDS - Acute lung injury

XXIV - Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.a

Pneumonitis (interstitial lung disease/ILD)

XXIX - Small airway involvement

XXIX.a

Bronchospasm - Wheezing - Asthma

XXXVI - Autoimmune syndromes - Systemic reactions or conditions

XXXVI.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)